Venus Remedies Ltd Locks at Upper Circuit With 5.0% Gain — Buyers Queue, Sellers Absent

Circuit Event and Unfilled Demand

The stock, trading in the EQ series, hit its upper circuit price band of 5%, closing at Rs 1411.3 after opening with a gap up of 4.83%. This price band capped the maximum daily gain allowed, effectively freezing trading at the ceiling price. The total traded volume was 2.38 lakh shares, generating a turnover of ₹33.27 crore. The exchange ceiling stopped the rally, not the buyers — demand exceeded what the price band could accommodate, leaving unfilled demand on the table. Venus Remedies Ltd touched a new 52-week and all-time high during the session, underscoring the strength of the move.

Delivery and Volume Analysis

Despite the upper circuit, delivery volumes tell a more nuanced story. On 1 Jun 2026, delivery volume fell by 39.18% compared to the 5-day average, with only 45,040 shares taken in delivery. This decline suggests that while the stock is hitting circuit, the buying may be more speculative or intraday-driven rather than backed by strong long-term conviction. Volume on a circuit day is mechanically suppressed because the price lock reduces liquidity, which means demand likely exceeded what the traded volume reflects — what does the full demand picture look like for Venus Remedies Ltd once the circuit unlocks and normal trading resumes? The total traded volume was lower than usual, a typical consequence of the circuit mechanism rather than a negative signal.

Moving Averages and Trend Context

Venus Remedies Ltd is trading comfortably above all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment confirms a strong bullish trend that preceded the circuit event. The stock has been on a consecutive seven-day gain streak, rising 36.95% over this period. The upper circuit day added another 5.0% to this momentum, reinforcing the breakout narrative. The intraday range was relatively narrow, from Rs 1355.1 to Rs 1411.3, indicating that the stock spent most of the session near the circuit price, consistent with the price band limit.

Liquidity and Market Capitalisation Context

With a market capitalisation of approximately ₹1,800 crore, Venus Remedies Ltd is classified as a micro-cap stock. The liquidity profile is moderate, with the stock liquid enough to support a trade size of around ₹0.23 crore based on 2% of the 5-day average traded value. While this is sufficient for retail and small institutional investors, it highlights the liquidity risk inherent in micro-cap stocks. Thin order books and limited trade sizes can amplify price moves and make it difficult to enter or exit positions without impacting the price. The upper circuit is impressive, but the ability to transact meaningful volumes without slippage remains constrained — should investors be cautious about liquidity risk despite the strong momentum?

Intraday Price Action

The stock opened at Rs 1344.5, quickly moving up to the circuit price of Rs 1411.3. The intraday low was Rs 1355.1, with the price steadily climbing throughout the session before locking at the upper circuit. This pattern is typical for circuit hits, where the price range narrows as the session progresses and the ceiling price is reached. The narrow range near the circuit price reflects the absence of sellers willing to transact below the ceiling, reinforcing the unfilled demand scenario.

Fundamental Snapshot

Venus Remedies Ltd operates in the Pharmaceuticals & Biotechnology sector, a space characterised by innovation and regulatory complexity. While the stock’s recent price action is driven by technical momentum and market dynamics, the underlying fundamentals such as revenue growth, profitability, and sector positioning remain important for assessing the sustainability of gains. The current circuit event does not directly reflect fundamental changes but rather market sentiment and liquidity factors.

Conclusion: Circuit, Delivery, and Liquidity Signals

The upper circuit hit at a 5% price band capped the session’s gains for Venus Remedies Ltd, with unfilled demand evident as buyers remained eager but sellers absent. However, the decline in delivery volume by 39.18% tempers the conviction narrative, suggesting that much of the buying may be speculative or intraday rather than long-term accumulation. The stock’s position above all major moving averages confirms a bullish trend, but the micro-cap status and moderate liquidity profile introduce a significant risk factor. Thin order books and limited trade sizes mean that while the momentum is strong, the ability to transact large volumes without price impact is constrained. After a 5.0% single-day gain at upper circuit, is Venus Remedies Ltd still worth considering or has the move already happened?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →